From KRAS^G12D to Pan-KRAS Inhibitors─A Journey Enabled by Synthetic Innovation and Structure-Based Drug Design

Area of Science:

• Oncology
• Medicinal Chemistry
• Drug Discovery

Background:

• KRAS is a key oncogene and historically challenging drug target.
• Recent success with KRAS G12C inhibitors like MK-1084 shows promise.
• Developing inhibitors for other KRAS mutations remains critical.

Purpose of the Study:

• To describe the discovery of KRAS G12D mutant-specific inhibitors.
• To highlight the use of synthetic innovations in drug discovery.
• To report the development of pan-KRAS inhibitors.

Main Methods:

• Structure-based drug design.
• Synthetic chemistry innovations.
• Structure-activity relationship studies.

Main Results:

• Identification of novel KRAS G12D mutant-specific inhibitors.
• Development of inhibitors with pan-RAS activity.
• Facilitation of drug discovery through advanced synthetic strategies.

Conclusions:

• Targeting specific KRAS mutations is feasible.
• Synthetic innovations and structure-based design are powerful tools for developing novel cancer therapeutics.
• The discovered inhibitors represent potential new treatments for KRAS-driven cancers.